New antibody eases hemophilia treatment

Article

A new antibody eases treatment of severe hemophilia A.

A new antibody eases treatment of severe hemophilia A. Japanese investigators studied emicizumab, a humanized bispecific antibody that mimics the cofactor function of factor VIII, in 18 patients with severe hemophilia A (with or without factor VIII inhibitors). Delivered subcutaneously weekly for 12 weeks, emicizumab markedly decreased the bleeding rate in these patients and was not associated with serious adverse events or clinically relevant coagulation abnormalities (Shima M, et al. N Engl J Med. 2016;374(2):2044-2053). 

Next: "No strings" prenatal income support improves birth outcomes

Ms Freedman is a freelance medical editor and writer in New Jersey. She has nothing to disclose in regard to affiliations with or financial interests in any organizations that may have an interest in any part of this article.

Recent Videos
Geetika Kennady, MD, FAAP
Jillian Cotter, MD
Jesse Hinckley, MD, PhD
Validating digital stethoscope for pediatric breath sounds, with Jennifer Nestor, MD
Decreasing antibiotics for acute otitis media and community acquired pneumonia, with Elysha Pifko, MD
Sensory play for children with autism, with Joshua Feder, MD
Stephanie Chao, MD
Feasibility of ambulatory blood pressure monitoring in primary care | Carissa Baker-Smith, MD, MPH
Tina Tan, MD
Camille Walker CPNP-PC, MSN, CPNP Sacheen D. Harris MSN, CPNP-PC
© 2025 MJH Life Sciences

All rights reserved.